raf Kinases

• 

  Subject Areas on Research

  • AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. 
  • Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. 
  • BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804). 
  • Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer. 
  • Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells. 
  • Increased expression of Drosophila tetraspanin, Tsp68C, suppresses the abnormal proliferation of ytr-deficient and Ras/Raf-activated hemocytes. 
  • Reelin signals survival through Src-family kinases that inactivate BAD activity. 
  • Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. 
  • Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. 
  • The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. 
  • The importance of the Erk pathway in the development of linker for activation of T cells-mediated autoimmunity. 
  • Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors. 
  • Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth. 
  • Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. 
• 

  Keywords of People

  • McLendon, Roger Edwin, Professor of Pathology, Pathology